Cost of known diabetes mellitus in Spain

被引:0
|
作者
Hart, WM
Espinosa, C
Rovira, J
机构
[1] SOIKOS,CTR ESTUDIOS ECON SALUT & POLIT SOCIAL,BARCELONA,SPAIN
[2] QF BAYER,BARCELONA,SPAIN
来源
MEDICINA CLINICA | 1997年 / 109卷 / 08期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Diabetes mellitus is an important cause of mortality and morbidity in western nations with high costs for both patients and healthcare systems. MATERIAL AND METHODS: Based on the latest epidemiological studies and in combination with Spanish demographic data the direct healthcare costs of known diabetes mellitus were estimated for the following areas: hospitalisation directly due to the disease, hospitalisation due to certain chronic complications such as acute myocardial infarction, amputations and renal disease (dialysis and transplant), outpatient visits, consumption of anti-diabetic medication, self-control, analyses, additional explorations and camps for diabetic children. RESULTS: In 1994, the total direct costs of diabetes mellitus in Spain were estimated to be more than 90,000 milions pesetas in a population of more than 1,400,000 known diabetic persons. This implies an average annual costs of approximately 63,000 pesetas per patient. If this cost is divided into categories, hospitalisation represents approximately 58% of the global cost, outpatient visits 14%, antidiabetic drugs 13%, self-control 4.7%, analyses 10% and camps a mere 0.04%. CONCLUSIONS: The most important component of the costs of diabetes mellitus in Spain in 1994 was hospitalisation due to the disease itself and its chronic complications which would seem to logically imply that resources ought to be targeted at reducing or postponing the development of such complications.
引用
收藏
页码:289 / 293
页数:5
相关论文
共 50 条
  • [31] CHD risk in persons with diabetes mellitus or with known coronary heart disease
    Wilson, PWF
    D'Agostino, RB
    Sullivan, L
    Vasan, RS
    CIRCULATION, 2002, 106 (19) : 509 - 509
  • [32] The cost of complications: implications for the measurement of the cost of type II diabetes mellitus
    Marissal, JP
    Gueron, B
    Dervaux, B
    REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE, 2006, 54 (02): : 137 - 147
  • [33] What Was Known About Childhood Diabetes Mellitus Before the Discovery of Insulin?
    Wright, James R.
    PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 2022, 25 (02) : 73 - 81
  • [34] Impact of known and newly diagnosed diabetes mellitus after a myocardial infarction
    Aguilar, D
    Solomon, SD
    Kober, L
    Rouleau, JL
    Skali, H
    McMurray, JJ
    Francis, GS
    Harris, M
    Diaz, R
    Belenkov, YN
    Varshavsky, S
    Leimberger, JD
    Califf, RM
    Pfeffer, MA
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 345A - 346A
  • [35] HEALTH INSURANCE COST OF DIABETES MELLITUS IN HUNGARY: A COST OF ILLNESS STUDY
    Gresz, M.
    Varga, S.
    Kriszbacher, I
    Sebestyen, A.
    Boncz, I
    VALUE IN HEALTH, 2010, 13 (07) : A288 - A288
  • [36] LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN SPAIN: A COST-EFFECTIVENESS ANALYSIS
    de Arellano Serna, Ramirez A.
    Mezquita-Raya, P.
    Vega-Hernandez, G.
    Wojcik, R.
    Schlueter, M.
    VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [37] ECONOMICS ANALYSIS OF DAPAGLIFLOZIN COMPARE TO SULFONYLUREA IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SPAIN: COST OF ACHIEVING COMPOSITE ENDPOINTS
    Capel, M.
    Cordero, L.
    VALUE IN HEALTH, 2015, 18 (07) : A609 - A610
  • [38] Hospitalizations due to severe hypoglycemia in patients with diabetes mellitus in Spain
    Lindner, L.
    Garcia-Sanchez, R.
    Alvarez, C.
    Betegon, L.
    Badia, X.
    REVISTA CLINICA ESPANOLA, 2013, 213 (08): : 370 - 376
  • [39] Impact of diabetes mellitus on kidney transplant recipients in Spain.
    Gonzalez-Posada, JM
    Marrero, DH
    Bayes, B
    Rivero, M
    Torres, A
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 655A - 655A
  • [40] Prostate Cancer Risk Among Men with Diabetes Mellitus (Spain)
    A. González-Pérez
    L.A. García Rodríguez
    Cancer Causes & Control, 2005, 16 : 1055 - 1058